Antagonism of cytotoxic T lymphocyte‐mediated lysis by natural HIV‐1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides

Mutations in human immunodeficiency virus (HIV) cluster in cytotoxic T lymphocyte (CTL) epitopes (Phillips, R. E. et al., Nature 1991. 354: 453) and are subject to immune‐mediated positive selection (Price, D. A. et al., Proc. Natl. Acad. Sci. USA 1997. 94: 1890). We studied the effects of naturally occurring mutations in the HIV‐1 p17 Gag HLA A2 restricted epitope SLYNTVATL on recognition by anti‐HIV CTL. Most of these naturally occurring mutants escaped killing by one CTL line and the majority acted as CTL antagonists. We also investigated whether CTL exposed to a strict antagonist peptide restricted by HLA A2 were unresponsive when exposed to targets presenting the wild‐type sequence. The results show that antagonism of anti‐HIV CTL killing requires the simultaneous presence of agonist and antagonist peptide. We found no evidence that CTL exposed to an antagonist received a functionally negative signal since these CTL retained an unimpaired capacity to lyse targets bearing wild‐type peptide.

[1]  R. Phillips,et al.  Patterns of Immunodominance in HIV-1–specific Cytotoxic T Lymphocyte Responses in Two Human Histocompatibility Leukocyte Antigens (HLA)-identical Siblings with HLA-A*0201 Are Influenced by Epitope Mutation , 1997, The Journal of experimental medicine.

[2]  P. Bjorkman,et al.  MHC Restriction in Three Dimensions: A View of T Cell Receptor/Ligand Interactions , 1997, Cell.

[3]  P. Klenerman,et al.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Stuart,et al.  Antagonist HIV-1 Gag Peptides Induce Structural Changes in HLA B8 , 1996, The Journal of experimental medicine.

[5]  P. Klenerman,et al.  Cytotoxic T Lymphocyte Lysis Inhibited by Viable HIV Mutants , 1995, Science.

[6]  P. Sharp,et al.  Cross-species transmission and recombination of 'AIDS' viruses. , 1995, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[7]  M. Busch,et al.  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group , 1995, Journal of virology.

[8]  A. Sette,et al.  Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. M. Howard,et al.  Sequence analysis of the glycoprotein 120 coding region of a new HIV type 1 subtype A strain (HIV-1IbNg) from Nigeria. , 1994, AIDS research and human retroviruses.

[10]  R. Young,et al.  Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 , 1994, The Journal of experimental medicine.

[11]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[12]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[13]  A. Sette,et al.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.

[14]  Sarah Rowland-Jones,et al.  Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.

[15]  D. Wiley,et al.  The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2 , 1993, Cell.

[16]  M. Bevan,et al.  Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells , 1993, The Journal of experimental medicine.

[17]  D. Burke,et al.  Phylogenetic analysis of gag genes from 70 international HIV‐1 isolates provides evidence for multiple genotypes , 1993, AIDS.

[18]  P. Allen,et al.  Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells , 1993, Nature.

[19]  T. Elliott,et al.  A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. , 1993, Journal of immunological methods.

[20]  M. Bevan,et al.  Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb‐restricted ovalbumin peptide and an assessment of the predictive power of MHC‐binding motifs , 1992, European journal of immunology.

[21]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[22]  Timothy E. Elliott,et al.  A quantitative assay of peptide‐dependent class I assembly , 1991, European journal of immunology.

[23]  Wei-Shau Hu,et al.  Retroviral recombination and reverse transcription. , 1990, Science.

[24]  D. Nixon,et al.  HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides , 1988, Nature.

[25]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[26]  R. L. Kahn,et al.  Complement Fixation with Protein Substances , 1918, The Journal of Immunology.

[27]  Zinkernagel Rm,et al.  Immunology - Promethean Viruses , 1994 .

[28]  J Sninsky,et al.  HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. , 1989, Journal of acquired immune deficiency syndromes.